Showing 21-25 of 25 results for "".
- Brickell Secures Rights to a Novel Class of RORγ Inhibitors for Psoriasis and Other Autoimmune Diseaseshttps://practicaldermatology.com/news/brickell-biotech-secures-rights-to-a-novel-class-of-ror-inhibitors-for-psoriasis-and-other-autoimmune-diseases/2458801/Brickell Biotech, Inc. has secured the exclusive world-wide rights to a series of novel retinoic acid–related orphan nuclear receptor gamma (RORy) inhibitors from Orca Pharmaceuticals (Orca) and New York University (NYU). This chemical series is based on intellectual property emerging from the labo…
- Aclaris Therapeutics Announces Positive Results from Phase IIb Trial of A-101 for the Removal of Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-announces-positive-results-from-phase-iib-trial-of-a-101-for-the-removal-of-seborrheic-keratosis/2459016/Aclaris Therapeutics, Inc. announced positive results from a Phase IIb clinical trial of the Company’s lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK). Though the lesions are benign, many patient…
- Aclaris Therapeutics Announces Positive Results from Phase II study of Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/20140702-aclaris_therapeutics_announces_positive_results_from_phase_ii_study_of_seborrheic_keratosis_treatment/2459181/Aclaris Therapeutics, Inc. announced positive results from a Phase II clinical trial of the its lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK). The double-blind, placebo-controlled Phase II clinical tri…
- NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indicationshttps://practicaldermatology.com/news/20140102-nexeption_llc_forms_new_company_alexar_therapeutics_inc_to_develop_novel_lxr_agonist_portfolio_for_dermatologic_indications/2459383/NeXeption, LLC, a biopharmaceutical management company that brings together product opportunities, management expertise and funding to reach compelling partnership milestones, has secured $21.5 million in Series A financing to form Alexar Therapeutics, Inc. Alexar is focused on developing an innova…
- "Cirque du CeraVe" Event in NYC Launches New CeraVe Productshttps://practicaldermatology.com/news/20121031-cirque_du_cerave_event_in_nyc_launches_new_cerave_products/2459687/The “Cirque du CeraVe” skincare launch event, held at Osteria del Circo in New York City on October, was attended by consumer, trade and dermatology media, who learned about new CeraVe product launches. The brand staged a CeraVe “Circus” complete with a professional mime, juggler, contortionist an…
- Previous
- Next